Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HypoxiSense 680
- Development stage
- Unknown
- Lead developer
- Revvity
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intravenous
01
Overview
HypoxiSense 680 (also known as IVISense Hypoxia CA IX 680) is a near-infrared (NIR) fluorescent in vivo imaging agent designed to target carbonic anhydrase IX (CA IX), a cell surface enzyme overexpressed in hypoxic tumor environments. Developed by PerkinElmer (now Revvity), the probe is synthesized by coupling the NIR fluorochrome IVISense 680 NHS (formerly VivoTag-680) to a derivative of the carbonic anhydrase inhibitor acetazolamide. It is used in preclinical research to non-invasively image and quantify regional tumor hypoxia and associated changes in animal models of cancer, angiogenesis, and inflammation.
- Brand names
- HypoxiSense 680HypoxiSense680HypoxiSense-680IVISense Hypoxia CA IX 680
- Other names
- HypoxiSense 680 Fluorescent ProbeHypoxiSense680 Fluorescent ProbeHypoxiSense-680 Fluorescent ProbeIVISense Hypoxia CA IX 680 Fluorescent Probe
02
Targets
CA2 (Carbonic Anhydrase 2)CA9 (Carbonic anhydrase IX)CA12 (Carbonic anhydrase XII)CA14 (Carbonic Anhydrase 14)
Beyond the preview
Go deeper on HypoxiSense 680.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HypoxiSense 680.